Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence
NCT07616531Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Randomised, open-label trial of genakumab in gout (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of patients experiencing at least one gout recurrence at 24 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT07616531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616531.